NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $261K invested in NLS Pharmaceutics Warrant in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
7.83% less ownership
Funds ownership: 13.31% → 5.47% (-7.8%)
38% less funds holding
Funds holding: 8 → 5 (-3)
46% less capital invested
Capital invested by funds: $485K → $261K (-$224K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$112K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$49K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $145K | – | – | – |
|
|
AC
2
Ayrton Capital
Westport,
Connecticut
| $49.3K | – | – | – |
|
|
ACM
3
Altium Capital Management
New York
| $38K | – | – | – |
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $27.7K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $1.09K | -$2.09K | -11,802 | -76% |
|
|
ACM
6
AIGH Capital Management
Baltimore,
Maryland
| – | -$112K | -633,361 | Closed |
|
|
WVP
7
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$49K | -194,060 | Closed |
|
NLSPW Hedge Fund Activity: Q4 2022 in Review
5 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q4 2022, worth a combined $261K — down 46% from $485K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NLSPW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was AIGH Capital Management, exiting entirely with an estimated $112K sold.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q4 2022, down from 8 in Q3 2022.
- Funds reported $261K of NLS Pharmaceutics Warrant stock for Q4 2022, down 46% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q4 2022 and 2 closed out, a net change of -2 holders.
- The largest NLS Pharmaceutics Warrant seller in Q4 2022 was AIGH Capital Management, an estimated $112K sold.
Based on aggregated 13F filings for Q4 2022.